Fri, Aug 29, 2014, 12:34 AM EDT - U.S. Markets open in 8 hrs 56 mins


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

viseslinger 4 posts  |  Last Activity: Aug 19, 2014 4:38 PM Member since: Oct 17, 2007
  • Reply to

    Maddi -- why no comment on this? Why no PR?

    by viseslinger Aug 18, 2014 9:33 PM
    viseslinger viseslinger Aug 19, 2014 4:38 PM Flag

    INCY IR does nothing. IR gets paid $ 250K / year to do nothing but eat donuts and drink coffee.

    This department should be renamed as "Sales Prevention" or "Sales Intervention" as is a far cry from IR

    Sentiment: Hold

  • Columbia University Medical Centre photo shows the effects of the drug ruxolitinib on a patient with severe alopecia. Photograph: Julian Mackay-Wiggan/PA

    Treatment with a drug normally used for a bone marrow condition has completely reversed baldness caused by alopecia in three patients, scientists in the US have announced. The sufferers had lost at least a third of the hair on their heads, and each regained total hair regrowth within five months of being treated with ruxolitinib, which is approved in the US and EU for treatment of myelofibrosis.

    One of the team from Columbia University Medical Centre, Professor Angela Christiano, has herself suffered from the condition, and described it as: "Not life threatening, but it is life altering".

    The results are announced in the online edition of Nature Medicine journal, by the team from Columbia, who previously identified the immune cells responsible for destroying the hair follicles. The treatment would not work for the more common male-pattern baldness, which is linked to hormones.

    The scientists tested two FDS-approved drugs known as JAK inhibitors, ruxolitinib and tofacitinib, on mice – where hair loss was completely reversed and the effects proved long lasting – and have now gone on to test ruxolitinib on human patients. Christiano said it was wrong to dismiss the condition as unimportant.

    "Nothing could be further from the truth. Patients with alopecia areata are suffering profoundly, and these findings mark a significant step forward for them. The team is fully committed to advancing new therapies for patients with a vast unmet need."

    In an interview with the New York Times, Christiano said the condition was first spotted by her hairdresser and then confirmed by a colleague with "a blood-curdling scream". It occurred almost 10 years ago when she had just arrived at Columbia to start her own laboratory, and she was told there was no cure – but in the interview, four years ago, she predicted that treatment co

    Sentiment: Hold

  • Reply to

    this about sums it up, hope it posts

    by tjnelis Jul 17, 2014 9:45 PM
    viseslinger viseslinger Jul 18, 2014 3:08 AM Flag

    Look at the MACD when INCY dropped from 70 to ~45 last time. Given that it appears as though INCY can fall an awful long way yet. Don't just look at RSI but also MACD.

    Sentiment: Hold

  • otherwise we can only assume we were left holding the "wet-bag" of Jims stock sales.

    Sentiment: Hold

53.94-0.77(-1.41%)Aug 28 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.